Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia

Summary

The main objectives of the trial are to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in adult hospitalized subjects with non-severe community-acquired pneumonia (CAP) or moderate / severe Coronavirus Disease 2019 (COVID-19) pneumonia. Other objectives are to determine pharmacokinetic (PK) and pharmacodynamic (PD) properties of trimodulin.

Timeline

Start

2022-12-22

Primary completion

2025-05-05

Completion

2025-05-05

Outcome

Outcome not reported

Stopped (Enrollment): “Unacceptable delay of trial completion Low recruitment rate”

Drugs

Indications